Cargando…
Liraglutide, 7,8-DHF and their co-treatment prevents loss of vision and cognitive decline in a Wolfram syndrome rat model
Wolfram syndrome (WS) is a monogenic progressive neurodegenerative disease and is characterized by various neurological symptoms, such as optic nerve atrophy, loss of vision, cognitive decline, memory impairment, and learning difficulties. GLP1 receptor agonist liraglutide and BDNF mimetic 7,8-dihyd...
Autores principales: | Seppa, Kadri, Jagomäe, Toomas, Kukker, Kaia Grete, Reimets, Riin, Pastak, Marko, Vasar, Eero, Terasmaa, Anton, Plaas, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838169/ https://www.ncbi.nlm.nih.gov/pubmed/33500541 http://dx.doi.org/10.1038/s41598-021-81768-6 |
Ejemplares similares
-
Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype
por: Jagomäe, Toomas, et al.
Publicado: (2021) -
Treatment with the dual-incretin agonist DA-CH5 demonstrates potent therapeutic effect in a rat model of Wolfram Syndrome
por: Jagomäe, Toomas, et al.
Publicado: (2023) -
GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome
por: Seppa, Kadri, et al.
Publicado: (2019) -
Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome
por: Toots, Maarja, et al.
Publicado: (2018) -
The Expression of RAAS Key Receptors, Agtr2 and Bdkrb1, Is Downregulated at an Early Stage in a Rat Model of Wolfram Syndrome
por: Punapart, Marite, et al.
Publicado: (2021)